Cargando...
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133(+) Cell Populations and Suppressing ERK/P70S6K Signaling
The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy because of its high frequency of chemoresistance. Metformin is widely used to treat type II diabetes, and was shown recently to inhibit pancreatic cancer stem cell proliferation. In the present study, we investiga...
Gardado en:
| Publicado en: | Sci Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4585731/ https://ncbi.nlm.nih.gov/pubmed/26391180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep14404 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|